RT Book, Section
A1 Lake, Douglas F.
A1 Briggs, Adrienne D.
A2 Katzung, Bertram G.
SR Print(0)
ID 1148441949
T1 Immunopharmacology
T2 Basic & Clinical Pharmacology, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259641152
LK accesspharmacy.mhmedical.com/content.aspx?aid=1148441949
RD 2024/04/24
AB CASE  STUDYA  45-year-old  man  with  high-risk  acute  myelogenous  leukemia  undergoes  high-dose  chemotherapy  followed  by  an  allogeneic  stem  cell  transplant  from  an  unrelated  donor.  He  receives  tacrolimus  and  low-dose  methotrexate  as  prophylaxis  for  graft-vs-host  disease.  One  month  after  blood  count  recovery,  he  develops  a  skin  rash  despite  ongoing  tacrolimus  therapy.  A  skin  biopsy  confirms  grade  II  acute  graft-vs-host  disease.  How  should  this  case  be  pharmacologically  managed  at  this  point?